// App-Quantinova.ai

P-26 : HERIZON-GEA-01: A phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (GEA)

Researchers

Presenter

  • J. Tabernero

Principal Investigators

  • E. Elimova

  • G. Ku

  • K. Shitara

  • L. Shen

  • T. Liu

  • X. Lin

  • L. Boyken

  • H. Li

  • J. Grim

  • J. Ajani

Medical Centers

  • Zymeworks Inc, Vancouver, Canada

  • Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain

  • National Cancer Center Hospital, Tokyo, Japan

  • Peking University Cancer Hospital & Institute, Beijing, China

  • Memorial Sloan Kettering Cancer Center, New York, United States

  • University of Texas MD Anderson Cancer Center, Houston, United States

  • Princess Margaret Cancer Centre, Toronto, Canada

  • Zhongshan Hospital Fudan University, Shanghai, China

Locations

  • Canada

  • United States

  • Spain

  • Japan

  • China

Companies

  • BeiGene (Beijing) Co

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroesophageal junction (GEJ) adenocarcinoma

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Adrucil injection

  • Tislelizumab

  • Capecitabine

  • Trastuzumab

  • Cisplatin

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved